News

As Seen In
Financial Post: Seeking to Cure the Incurable
To read the article on the Financial Post website click here.\n\nCanada and Japan are taking...
As Seen In
Streetwise Report Interviews BioWatch News Founder Alan Leong
To read the full report, click here. Biotechnology can be daunting to comprehend, but understanding...
Press Release
RepliCel Submits Clinical Trial Application for its Dermatological Clinical Trial
Autologous cell therapy, RCS-01, to be investigated as a potential treatment for aged, UV-damaged skin...
As Seen In
The Total Tutor Interviews CEO David Hall on BlogTalkRadio
RepliCel’s CEO David Hall is interviewed by The Total Tutor Neil Haley on blogtalkradio. Hall...
As Seen In
Houston Style Magazine Interviews RepliCel CEO
 New Treatment for NFL Players and Pro Athletes Offers New HopeStory by: Jo-CarolynNew York, NY,...
As Seen In
CEO David Hall Interviewed on ESPN New York Radio
To listen to the full interview, click here or view the file below. CEO &...
Events
RepliCel Life Sciences to Present at 11th Annual Phacilitate Cell & Gene Therapy Forum in Washington, DC
VANCOUVER, BC – January 20, 2015 – RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: REPCF),...
Events
RepliCel Life Sciences to Present at Biotech Showcase 2015
Meetings focused on investors, analysts, and potential partners for RCS-01 and RCT-01 cell therapiesVANCOUVER, BC...
Press Release
Newly Released Peer-Reviewed Publication Further Validates RepliCels Use of Dermal Sheath Cup Cells to Treat Pattern Baldness
VANCOUVER, BC – December 22, 2014 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP),...
As Seen In
VP Lee Buckler Podcast Interview by Midas Letter
Written By: James West Listen to the full interview here. RepliCel’s VP Lee Buckler explains...
As Seen In
Chronic Achilles Tendinosis Video Launched
Using Your Own Cells to Heal Tendon InjuriesRepliCel is developing an autologous cell-based product for...
Events
RepliCel Life Sciences to Present at World Stem Cell Summit 2014
Over multiple sessions, Lee Buckler will present a RepliCel update, participate in session panels, and...
Press Release
RepliCel Life Sciences Receives Health Canada Clearance for Clinical Trial in Patients with Chronic Achilles Tendinosis
Health Canada Issues “No Objection Letter” for RepliCel’s Phase 1/2 Clinical Trial of RCT-01 VANCOUVER,...
Press Release
RepliCel Announces 2014 Third Quarter Financial Results
VANCOUVER, BC – November 26, 2014 – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”)...
As Seen In
November 7, 2014 – R. Lee Buckler: How RepliCel is Harnessing the Awesome Power of Cell Therapy
To read the full report, click here: R. Lee Bucker on RepliCel Life SciencesRegenerative medicine...
Press Release
RepliCel Submits Clinical Trial Application to Health Canada for its Chronic Achilles Tendinosis Trial
Autologous cell therapy, RCT-01, to be investigated for treatment of tendinopathies refractory to other treatments...
As Seen In
Midas Letter Interviews CEO David Hall
To listen to the full interview podcast and read the transcript click here: Midas Letter...
As Seen In
Japan Gives a Hug to the Cell Therapy Industry: R. Lee Buckler
To read the full report click here: R. Lee Buckler on the Cell Therapy IndustryLast...
As Seen In
Seeking Alpha – Why RepliCel is a Promising Under-Researched Small-Cap Biotech
By: Eric Chiu, Biotech, Healthcare Contributor Published October 10, 2014To read the entire article as...
Events
RepliCel to Present Commercial and Clinical Update at BioJapan 2014 World Business Forum
Japanese meetings to focus on partnering VANCOUVER, BC – October 9, 2014 – RepliCel Life...

DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.